SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lorizio W.)
 

Sökning: WFRF:(Lorizio W.) > CYP2D6 Genotype and...

  • Province, M. A.Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis MO, USA (författare)

CYP2D6 Genotype and Adjuvant Tamoxifen : Meta-Analysis of Heterogeneous Study Populations

  • Artikel/kapitelEngelska2014

Förlag, utgivningsår, omfång ...

  • 2013-09-23
  • New York, USA :Nature Publishing Group,2014
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-33895
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-33895URI
  • https://doi.org/10.1038/clpt.2013.186DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies:National Institutes of Health (National Institute of General Medical Sciences)National Institutes of Health (National Cancer Institute)National Institutes of Health (National Institute of Child Health and Human Development)Breast Cancer Research (Scotland)  Tayside Tissue Bank  California Breast Cancer Research Program Cancer Research UK  Deutsches Krebsforschungszentrum, Heidelberg, Germany  Robert Bosch Foundation, Stuttgart, Germany  Marie Curie Initial Training Network "FightingDrugFailure" GrantStichting Emmanuel van der Schueren (scientific partner of the Vlaamse Liga tegen Kanker)  National Project for Personalized Genomic Medicine, Ministry for Health & Welfare, Republic of Korea Deutsche Forschungsgemeinschaft, Germany 
  • The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1), CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Goetz, M. P.Department of Oncology and Pharmacology, Mayo Clinic, Rochester MN, USA (författare)
  • Brauch, H.Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Tübingen University, Tübingen, Germany (författare)
  • Flockhare, D. A.Division of Clinical Pharmacology, School of Medicine, Indiana University, Bloomington IN, USA (författare)
  • Hebert, J. M.Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA (författare)
  • Whaley, R.Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA (författare)
  • Suman, V. J.Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester MO, USA (författare)
  • Schroth, W.Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Tübingen University, Tübingen, Germany (författare)
  • Winter, S.Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology and University, Tuebingen, Germany (författare)
  • Zembutsu, H.Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan (författare)
  • Mushiroda, T.Laboratory for Pharmacogenetics, RIKEN Center for Genomic Medicine, Yokohama, Japan (författare)
  • Newman, W. G.Centre for Genetic Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK (författare)
  • Lee, M-TM.Laboratory for International Alliance, RIKEN Center for Genomic Medicine, Yokohama, Japan (författare)
  • Ambrosone, C. B.Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo NY, USA (författare)
  • Beckmann, M. W.Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany (författare)
  • Choi, J-YDepartment of Biomedical Science, Graduate School, Seoul National University, Seoul, Korea (författare)
  • Dieudonne, A-SDepartment of Oncology, Catholic University Leuven, Leuven, Belgium (författare)
  • Fasching, P. A.Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles CA, USA (författare)
  • Ferraldeschi, R.Centre for Genetic Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK (författare)
  • Gong, L.Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA (författare)
  • Haschke-Becher, E.University Institute of Medical and Chemical Laboratory Diagnostics, Paracelsus Private Medical University, Salzburg, Austria (författare)
  • Howel, A.The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK (författare)
  • Jordan, L. B.Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK (författare)
  • Hamann, U.Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum, Heidelberg, Germany (författare)
  • Kiyotani, K.Laboratory for Pharmacogenetics, RIKEN Center for Genomic Medicine, Yokohama, Japan (författare)
  • Krippl, P.Medical University Graz, Graz, Austria (författare)
  • Lambrechts, D.Vesalius Research Center, VIB and Laboratory of Translational Genetics, Department of Oncology, Catholic University Leuven, Leuven, Belgium (författare)
  • Latif, A.Centre for Genetic Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK (författare)
  • Langsenlehner, U.Medical University Graz, Graz, Austria (författare)
  • Lorizio, W.Division of General Internal Medicine, Department of Medicine and Clinical Pharmacology and Experimental Therapeutics, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco CA, USA (författare)
  • Neven, P.Department of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium (författare)
  • Nguyen, A. T.Division of Clinical Pharmacology, School of Medicine, Indiana University, Bloomington IN, USA (författare)
  • Park, B-W.Department of Surgery, Yonsei University Health System, Seoul, Korea (författare)
  • Purdie, C. A.Department of Pathology, Ninewells Hospital and Medical School, Dundee, UK (författare)
  • Quinlan, P.Dundee Cancer Centre, Dundee, UK (författare)
  • Renner, W.Medical University Graz, Graz, Austria (författare)
  • Schmidt, M.Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University Tübingen, Tübingen, Germany; Department of Gynecology and Obstetrics, University of Mainz, Mainz, Germany (författare)
  • Schwab, M.Department of Clinical Pharmacology and Toxicology, University Hospital Tuebingen, Tuebingen, Germany (författare)
  • Shin, J-GDepartment of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine, Busan, Korea; Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, Korea (författare)
  • Stingl, J. C.Division of Research, Federal Institute for Drugs and Medical Devices, University of Bonn Medical Faculty, Bonn, Germany (författare)
  • Wegman, Pia,1964-Örebro universitet,Hälsoakademin(Swepub:oru)ppk (författare)
  • Wingren, Sten,1950-Örebro universitet,Institutionen för läkarutbildning(Swepub:oru)snwn (författare)
  • Wu, A. H. B.Department of Laboratory Medicine, University of California, San Francisco CA, USA (författare)
  • Ziv, E.Division of General Internal Medicine, Department of Medicine and Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco CA, USA (författare)
  • Zirpoli, G.Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo NY, USA (författare)
  • Thompson, A. M.Dundee Cancer Centre, Dundee, UK (författare)
  • Jordan, V. C.Department of Oncology, Georgetown University, Washington DC, USA (författare)
  • Nakamura, Y.Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan (författare)
  • Altman, R. B.Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA; Department of Bioengineering, Stanford University, Stanford CA, USA (författare)
  • Ames, M. M.Department of Pharmacology, Mayo Clinic, Rochester MN, USA (författare)
  • Klein, T. E.Department of Genetics, School of Medicine, Stanford University, Stanford CA, USA (författare)
  • Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis MO, USADepartment of Oncology and Pharmacology, Mayo Clinic, Rochester MN, USA (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Clinical Pharmacology and TherapeuticsNew York, USA : Nature Publishing Group95:2, s. 216-2270009-92361532-6535

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy